FDC Ltd.

BSE: FDC531599ISIN INE258B01022

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹391.15+2.60 (+0.67%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹468.95
52W low: ₹314.75
Off 52W high: -16.59%
1M return: +17.94%
3M return: +0.94%
6M return: +5.13%
1Y return: -12.60%
20D avg volume: 18,906
50 DMA: ₹348.31
200 DMA: ₹370.95

Key ratios Consolidated

Market cap: ₹6,368 Cr
Current price: ₹391.15
52W high / low: ₹468.95 / ₹314.75
Face value: ₹1.00
P/E: 20.33
P/B: 2.39
EPS (TTM): ₹19.24
Book value / share: ₹163.94
ROE: —
ROCE: 14.90%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-48.68 Cr
Interest cover: 76.07
Dividend yield: 1.28%
Dividend / share (TTM): ₹5.00
Payout: 25.99%
Cash conversion cycle: 50.4 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	572.14	667.69	584.79	464.71	473.03	648.41	491.89	464.11	513.85	638.27	462.03	458.17
	17.94	47.66	49.89	20.80	20.62	35.50	16.08	18.83	34.70	28.44	20.27	24.70
	590.08	715.35	634.68	485.51	493.66	683.91	507.97	482.94	548.55	666.71	482.30	482.87
	524.67	540.65	494.33	428.33	455.57	524.13	454.66	431.76	458.55	503.97	417.10	385.33
	139.94	144.50	148.93	108.47	140.66	178.31	156.64	148.91	139.98	135.72	149.80	142.41
	29.91	21.48	41.78	17.63	33.91	34.28	32.62	25.97	32.64	36.21	34.79	27.40
	134.28	135.16	109.30	120.08	120.79	132.37	121.61	118.60	124.95	117.21	103.25	103.51
	0.84	0.83	1.55	1.12	1.15	1.17	1.19	0.95	1.07	1.30	0.95	0.97
	15.98	15.13	14.36	14.78	15.20	14.91	15.56	13.36	13.79	11.02	10.44	9.97
	188.43	175.89	163.51	140.79	173.86	166.45	154.96	137.94	135.71	143.46	—	—
	65.41	174.70	140.35	57.17	38.09	159.78	53.31	51.18	90.00	162.74	65.21	97.55
	0.00	0.00	0.00	-20.79	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	65.41	174.70	140.35	36.38	38.09	159.78	53.31	51.18	90.00	162.74	65.21	97.55
	16.35	42.21	36.95	8.08	9.72	38.42	14.64	14.14	17.95	43.70	18.93	18.37
	49.06	132.49	103.40	28.30	28.37	121.35	38.67	37.04	72.04	119.03	46.28	79.17
	3.01	8.14	6.35	1.74	1.75	7.45	2.38	2.28	4.43	7.31	2.84	4.86
Key metrics
	82.23	190.66	156.26	52.28	54.44	175.86	70.06	65.49	104.86	175.06	76.60	108.49
	14.40%	28.60%	26.70%	11.30%	11.50%	27.10%	14.20%	14.10%	20.40%	27.40%	16.60%	23.70%
	8.60%	19.80%	17.70%	6.10%	6.00%	18.70%	7.90%	8.00%	14.00%	18.60%	10.00%	17.30%
	2.40%	—	5.60%	—	1.60%	—	2.30%	—	—	—	—	—
	21.00%	3.00%	18.90%	0.10%	-7.90%	1.60%	6.50%	1.30%	—	—	—	—
	72.90%	9.20%	167.40%	-23.60%	-60.60%	1.90%	-16.40%	-53.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	2,289	2,171	2,108	1,943	1,784	1,528
	136.29	113.52	90.66	101.63	49.86	76.09
	2,426	2,284	2,199	2,045	1,834	1,604
	1,988	1,889	1,842	1,648	1,576	1,315
	541.84	576.37	581.24	584.57	585.92	454.24
	110.80	127.60	127.44	125.06	85.01	141.40
	498.82	482.55	482.37	413.40	390.89	343.33
	4.34	4.99	4.51	4.03	4.09	3.09
	60.25	59.24	53.73	39.92	38.94	37.30
	668.62	631.32	564.68	—	—	—
	437.63	395.39	357.22	396.22	257.80	289.39
	-20.79	-20.79	0.00	0.00	0.00	0.00
	416.84	374.60	357.22	396.22	257.80	289.39
	103.59	93.18	90.43	91.16	63.98	73.22
	313.25	281.42	266.79	305.06	193.83	216.16
	19.24	17.29	16.39	18.58	11.66	12.81
Key metrics
	481.43	438.83	415.46	440.17	300.83	329.78
	21.03%	20.20%	19.70%	22.70%	16.90%	21.60%
	13.68%	13.00%	12.70%	15.70%	10.90%	14.10%
	—	14.90%	15.40%	—	—	—
	10.20%	3.00%	8.50%	8.90%	16.70%	—
	38.96%	5.50%	-12.50%	57.40%	-10.30%	—
	—	13.89	220.85	—	—	—
	—	0.71	1.19	—	—	—
	—	0.00	0.00	—	—	—
	—	-48.68	-51.36	—	—	—
	—	50.4	48.2	—	—	—
Balance sheet
	—	2,919	2,714	—	—	—
	—	1,133	1,085	—	—	—
	—	48.68	51.47	—	—	—
	—	151.72	108.85	—	—	—
	—	355.25	375.03	—	—	—
	—	92.33	57.60	—	—	—
	—	952.37	848.04	—	—	—
	—	206.79	205.15	—	—	—
	—	364.07	361.64	—	—	—
	—	0.00	0.11	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.11	—	—	—
	—	2,485	2,281	—	—	—
Cash flow
	—	200.45	317.57	—	—	—
	—	-109.93	-199.51	—	—	—
	—	-93.33	-92.12	—	—	—
	—	186.56	96.72	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	552.79	655.10	564.36	457.94	461.74	642.28	482.00	458.86	505.10	624.14	454.23	452.21
	18.62	47.34	47.16	22.07	20.91	35.59	31.43	18.64	34.68	28.15	20.72	25.33
	571.41	702.44	611.53	480.01	482.65	677.87	513.43	477.51	539.78	652.29	474.95	477.55
	507.88	528.17	468.56	424.20	443.16	516.98	445.89	427.19	447.53	494.74	407.73	381.21
	137.57	141.16	142.59	106.84	137.25	175.66	154.69	146.79	139.08	135.14	147.27	142.41
	26.55	21.46	29.18	20.98	31.16	34.23	32.03	28.16	28.42	31.51	33.93	25.37
	132.76	133.73	107.40	118.39	119.14	131.14	119.87	117.56	123.86	115.94	101.64	102.53
	0.83	0.82	1.50	1.12	1.15	1.16	1.18	0.94	1.07	1.29	0.94	0.97
	15.95	15.09	14.31	14.75	15.17	14.87	15.53	13.32	13.76	11.00	10.39	9.93
	179.31	169.60	155.15	137.58	168.43	162.63	149.38	134.98	132.21	139.07	—	—
	63.53	174.27	142.97	55.81	39.49	160.88	67.54	50.32	92.25	157.56	67.22	96.33
	0.00	0.00	0.00	-20.79	0.00	0.00	0.00	—	—	—	—	—
	63.53	174.27	142.97	35.02	39.49	160.88	67.54	50.32	92.25	157.56	67.22	96.33
	15.84	42.25	35.89	7.83	10.02	38.69	19.33	13.87	18.28	42.57	19.02	17.96
	47.69	132.02	107.07	27.19	29.48	122.19	48.22	36.45	73.97	114.99	48.19	78.38
	2.93	8.11	6.58	1.67	1.81	7.51	2.96	2.24	4.55	7.06	2.97	4.81
Key metrics
	80.31	190.18	158.78	50.89	55.81	176.91	84.25	64.58	107.08	169.85	78.55	107.23
	14.50%	29.00%	28.10%	11.10%	12.10%	27.50%	17.50%	14.10%	21.20%	27.20%	17.30%	23.70%
	8.60%	20.20%	19.00%	5.90%	6.40%	19.00%	10.00%	7.90%	14.60%	18.40%	10.60%	17.30%
	2.30%	—	5.60%	—	1.60%	—	2.90%	—	—	—	—	—
	19.70%	2.00%	17.10%	-0.20%	-8.60%	2.90%	6.10%	1.50%	—	—	—	—
	61.80%	8.00%	122.00%	-25.40%	-60.10%	6.30%	0.10%	-53.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	2,230	2,126	2,070	1,916	1,777	1,519
	135.19	111.00	105.52	103.22	53.91	78.73
	2,365	2,237	2,176	2,019	1,831	1,598
	1,929	1,838	1,808	1,621	1,565	1,312
	528.16	562.35	575.69	582.04	585.36	453.50
	98.17	115.55	120.12	118.54	80.78	139.60
	492.28	476.07	477.22	408.99	386.99	339.97
	4.27	4.92	4.49	4.00	4.04	3.05
	60.10	59.10	53.61	39.73	38.76	37.08
	641.64	609.06	548.25	—	—	—
	436.58	399.15	367.67	397.94	265.69	285.45
	-20.79	-20.79	0.00	—	—	—
	415.79	378.36	367.67	397.94	265.69	285.45
	101.81	92.44	94.05	90.78	64.72	65.81
	313.97	285.92	273.63	307.16	200.97	219.64
	19.29	17.56	16.81	18.70	12.09	13.01
Key metrics
	480.16	442.38	425.77	441.67	308.49	325.58
	21.53%	20.80%	20.60%	23.00%	17.40%	21.40%
	14.08%	13.40%	13.20%	16.00%	11.30%	14.50%
	—	15.00%	15.80%	—	—	—
	9.06%	2.70%	8.00%	7.80%	17.00%	—
	32.85%	4.50%	-10.90%	52.80%	-8.50%	—
	—	13.87	213.72	—	—	—
	—	0.70	1.13	—	—	—
	—	0.00	0.00	—	—	—
	—	-37.47	-39.67	—	—	—
	—	49.0	47.6	—	—	—
Balance sheet
	—	2,912	2,710	—	—	—
	—	1,109	1,065	—	—	—
	—	37.47	39.67	—	—	—
	—	142.37	103.88	—	—	—
	—	343.66	367.70	—	—	—
	—	92.20	57.33	—	—	—
	—	947.90	844.00	—	—	—
	—	200.22	201.52	—	—	—
	—	354.22	355.01	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	2,493	2,287	—	—	—
Cash flow
	—	200.17	310.34	—	—	—
	—	-109.24	-199.45	—	—	—
	—	-93.15	-92.10	—	—	—
	—	186.30	96.62	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +6.16%
Sales CAGR 5Y: —
Profit CAGR 3Y: +12.47%
Profit CAGR 5Y: —
Sales YoY (TTM): +9.06%
Profit YoY (TTM): +32.85%

Consolidated

Sales CAGR 3Y: +6.77%
Sales CAGR 5Y: —
Profit CAGR 3Y: +13.23%
Profit CAGR 5Y: —
Sales YoY (TTM): +10.20%
Profit YoY (TTM): +38.96%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 69.65%

Quarter	September 2026	June 2026
Promoter %	69.65%	69.65%

Holder	Type	Holding	Previous	Change
NOMITA R CHANDAVARKAR	Promoter	22.67%	22.67%	0.00%
NANDAN MOHAN CHANDAVARKAR (In the capacity of Trustee of Mohan Anand Chandavarkar Trust)	Promoter	12.45%	12.45%	0.00%
NANDAN MOHAN CHANDAVARKAR (In the capacity of Trustee of Sandhya Mohan Chandavarkar Trust)	Promoter	12.45%	12.45%	0.00%
Leo Advisors Private Limited (In capacity of Trsutee of Ameya Family Discretionary Trust)	Promoter Group	9.17%	—	—
ADITI C BHANOT	Promoter	6.80%	6.80%	0.00%
AMEYA ASHOK CHANDAVARKAR	Promoter	6.10%	6.10%	0.00%
ICICI PRUDENTIAL SMALLCAP FUND	Public	2.91%	2.80%	+0.11%
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA SMALL CAP FUND	Public	2.63%	2.63%	0.00%
NANDAN MOHAN CHANDAVARKAR	Promoter	0.01%	0.01%	0.00%
Capt. Girish Anand Kaushik	Promoter Group	0.00%	0.00%	0.00%
Veera Ameya Chandavar	Promoter Group	0.00%	0.00%	0.00%
Roma Bhanot	Promoter Group	0.00%	0.00%	0.00%
Vasant Anand Chandavarkar	Promoter Group	0.00%	0.00%	0.00%
Vivekanand Hemmad	Promoter Group	0.00%	0.00%	0.00%
ALPANA NANDAN CHANDAVARKAR	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
FDC Ltd.	6,368	391.15	20.33	14.90%	+10.20% TTM	+38.96% TTM	-12.60%

Filings & corporate actions

Recent announcements

This is to inform that the Company has received favourable orders from the Assistant Commissioner of Income Tax, Mumbai, for AY 2016-17.4 Nov 2026 · Others
This is to inform that the Company has received favourable orders from the Assistant Commissioner of Income Tax, Mumbai, for AY 2014-15 and AY 2012-13.31 Oct 2026 · Others
Sundae Capital Advisors Private Limited ("Manager to the Offer") has submitted to BSE a copy of Public Announcement for the attention of Equity Shareholders / Beneficial Owners of the Equity ....29 Oct 2026 · Company Update / General
Newspaper advertisement in respect of the Buyback of Shares29 Oct 2026 · Company Update / Public Announcement-Buyback of Shares
The Board has approved the proposal of Buyback of equity shares of the company.28 Oct 2026 · Company Update / General
The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 202627 Oct 2026 · Result / Financial Results
The Board of Directors, at its Meeting held today, has approved the Buyback of Equity Shares. The record date for the same is November 13, 2026.27 Oct 2026 · Corp. Action / Record Date
The Board Has Decided November 13, 2026, as the Record Date For the buyback Offer.27 Oct 2026 · Company Update / Buy back
Press Release Q2 FY 2026-27 Results.27 Oct 2026 · Company Update / Press Release / Media Release
Outcome of the Board Meeting held today i.e. Tuesday, October 27, 202627 Oct 2026 · Board Meeting / Outcome of Board Meeting
FDC Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve This is to inform you that a meeting of ....21 Oct 2026 · Board Meeting / Board Meeting
Certificate under Regulation 74(5) of the SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended September 30, 2026.7 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Disclosure of Voting results of the 86th Annual general Meeting held on 24th September, 2026 along with the Scrutinizer''s Report.28 Sep 2026 · AGM/EGM / AGM
Trading window of the Company shall remain closed for all the Designated Persons and their relatives with effect from 1st October , 2026, till 48 hours after the declaration of Unaudited ....25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Proceedings of the 86th Annual General Meeting held on Thursday, 24th September 2026.24 Sep 2026 · AGM/EGM / AGM
Newspaper Publication - Corrigendum to 86th AGM Notice- Cut-off date & Book Closure period FY 2025-26.18 Sep 2026 · Company Update / Newspaper Publication
This is to inform you that a typographical error has occurred in the notice of the 86th AGM for FY 2025-26. The cutoff date for e-voting shall be read as September 17, 2026, instead of ....17 Sep 2026 · AGM/EGM / AGM
Newspaper Publication of the convening of the 86th Annual General Meeting of the Company.4 Sep 2026 · Company Update / Newspaper Publication
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nandan Mohan Chandavarkar, Mohan Anand ....3 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
BRSR for FY 2025-261 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
This is to inform you that the register of members and share transfer books of the Company will remain closed from Thursday, September 17, 2026, to Wednesday, September 23, 2026 (both days ....1 Sep 2026 · Corp. Action / Book Closure
Annual Report for FY 2025-261 Sep 2026 · Others / Reg. 34 (1) Annual Report
Please find enclosed Notice of 86th Annual General meeting for the FY 2025-261 Sep 2026 · AGM/EGM / AGM
Please find attached copies of the newspaper advertisement in respect of the 86th AGM of the Company1 Sep 2026 · Company Update / Newspaper Publication
Announcement under Regulation 3027 Aug 2026 · Company Update / General
This is to inform you that the company''s Subsidiary, FDC International Ltd., has received Marketing Authorisation from the MHRA, UK, for Atropine 1.0% w/v Eye Drops, Solution.13 Aug 2026 · Company Update / General
Press Release Q1 FY 2026-27 Results.5 Aug 2026 · Company Update / Press Release / Media Release
Financial Results for the quarter ended June 30, 20265 Aug 2026 · Result / Financial Results
Outcome for the Board Meeting Held on 5th August, 2026.5 Aug 2026 · Board Meeting / Outcome of Board Meeting
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 202627 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
FDC Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting to be held ....23 Jul 2026 · Board Meeting / Board Meeting
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sandhya Mohan Chandavarkar Trust (through its ....29 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mohan Anand Chandavarkar Trust (through its ....29 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nandan Mohan Chandavarkar & PACs29 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Trading Window of the Company shall remain closed for all the Designated persons, Connected persons and their relative(s) with effect from July 01, 2026, till 48 hours after the declaration ....26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Announcement under Regulation 30 of SEBI (LODR) Regulation, 20154 Jun 2026 · Company Update / General
Please find attached the outcome of Postal Ballot28 May 2026 · AGM/EGM / Postal Ballot
Please find attached the scrutinizer report for Postal Ballot28 May 2026 · AGM/EGM / Postal Ballot
Annual Secretarial Compliance report of FDC Limited for Financial year ending March 31, 2026.28 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
This is with regards to our intimation made on May 27, 2026 for Press Release wherein there was typographical error in the Subject line of Press Release in the mentioned year, which shall ....28 May 2026 · Company Update / Press Release / Media Release (Revised)

Corporate actions

Purpose	Ex date	Record date	Payment date
Buy Back of Shares	13 Nov 2026	13 Nov 2026	—
Interim Dividend - Rs. - 5.0000	11 Feb 2026	11 Feb 2026	—
Interim Dividend - Rs. - 5.0000	22 Nov 2024	22 Nov 2024	—

Board meetings

27 Oct 2026 Board Meeting - Financial Results
5 Aug 2026 Board Meeting - Financial Results